Protection Against Developmental Deficiencies by a Lipophilic VIP Analogue

[1]  S. Said.  Molecules that protect: the defense of neurons and other cells. , 1996, The Journal of clinical investigation.

[2]  I. Gozes,et al.  A femtomolar-acting neuroprotective peptide. , 1996, The Journal of clinical investigation.

[3]  H. Wiśniewski,et al.  In Vivo Structural Studies of the Hippocampus in Normal Aging and in Incipient Alzheimer's Disease a , 1996, Annals of the New York Academy of Sciences.

[4]  I. Gozes,et al.  Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. , 1995, The Journal of pharmacology and experimental therapeutics.

[5]  D. Mann,et al.  Apolipoprotein E epsilon 2 allele promotes longevity and protects patients with Down's syndrome from dementia. , 1994, Neuroreport.

[6]  P. Gressens,et al.  Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse. , 1994, The Journal of clinical investigation.

[7]  I. Gozes,et al.  Blockade of VIP during Neonatal Development Induces Neuronal Damage and Increases VIP and VIP Receptors in Brain , 1994, Annals of the New York Academy of Sciences.

[8]  I. Gozes,et al.  Stearyl-norleucine-vasoactive intestinal peptide (VIP): a novel VIP analog for noninvasive impotence treatment. , 1994, Endocrinology.

[9]  I. Gozes,et al.  Diurnal oscillation in vasoactive intestinal peptide gene expression independent of environmental light entraining , 1994, Brain Research.

[10]  A. Fatatis,et al.  Vasoactive intestinal peptide increases intracellular calcium in astroglia: synergism with alpha-adrenergic receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[11]  H. Kobayashi,et al.  Effects of vasoactive intestinal peptide (VIP) on scopolamine-induced amnesia in the rat , 1994, Neuropeptides.

[12]  A. Takashima,et al.  Influence of chronic intracerebroventricular infusion of vasoactive intestinal peptide (VIP) on memory processes in Morris water pool test in the rat , 1993, Peptides.

[13]  M. Fujino,et al.  Effects of vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) on the spontaneous release of acetylcholine from the rat hippocampus by brain microdialysis , 1993, Brain Research.

[14]  P. Magistretti,et al.  Neurotransmitters regulate energy metabolism in astrocytes: implications for the metabolic trafficking between neural cells. , 1993, Developmental neuroscience.

[15]  M. Tohyama,et al.  Axonal blockade induces the expression of vasoactive intestinal polypeptide and galanin in rat dorsal root ganglion neurons , 1992, Brain Research.

[16]  L. Panlilio,et al.  Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist , 1992, Brain Research.

[17]  A. Ho,et al.  Differential Involvement of the Arachidonic Acid Cascade on the α1‐Adrenergic Potentiation of Vasoactive Intestinal Peptide‐Versus β‐Adrenergic‐Stimulated Cyclic AMP and Cyclic GMP Accumulation in Rat Pinealocytes , 1991, Journal of neurochemistry.

[18]  B. Pappas,et al.  The histopathological, behavioral and neurochemical effects of intraventricular injection of ethylcholine mustard aziridinium (AF64A) in the neonatal rat. , 1991, Brain research. Developmental brain research.

[19]  D. Agoston,et al.  Spontaneous electrical activity regulates vasoactive intestinal peptide expression in dissociated spinal cord cell cultures. , 1991, Brain research. Molecular brain research.

[20]  I. Gozes,et al.  Vasoactive intestinal peptide antagonist retards the development of neonatal behaviors in the rat , 1991, Peptides.

[21]  J. Morley,et al.  Vasoactive intestinal peptide (VIP): An amnestic neuropeptide , 1990, Peptides.

[22]  S. Gitter,et al.  Central catecholaminergic dysfunction and behavioral disorders following hypoxia in adult rats , 1990, Behavioural Brain Research.

[23]  W. Moos,et al.  A Simplified Procedure for Preparing the Cholinergic Neurotoxin 1-Ethyl-1-(2-hydroxyethyl)aziridinium Ion (AF64A). , 1989 .

[24]  R. Malach,et al.  Disruption of the optic pathway during development affects vasoactive intestinal peptide mRNA expression. , 1989, The New biologist.

[25]  I. Gozes,et al.  Vasoactive intestinal peptide potentiates sexual behavior: Inhibition by novel antagonist , 1989, Regulatory Peptides.

[26]  A. Fisher,et al.  (±)-cis-2-Methyl-spiro(1,3-oxathiolane-5,3′) quinuclidine (AF102B): A new M1 agonist attenuates cognitive dysfunctions in AF64A-treated rats , 1989, Neuroscience Letters.

[27]  W. Moos,et al.  A SIMPLIFIED PROCEDURE FOR PREPARING THE CHOLINERGIC NEUROTOXIN 1-ETHYL-1-(2-EYDROXYETHYL)AZIRIDINIUM ION (AF64A) , 1989 .

[28]  C. Finch,et al.  The neurobiology of Alzheimer's disease. , 1989, Journal of neurosurgery.

[29]  I. Gozes,et al.  Vasoactive intestinal peptide gene expression from embryos to aging rats. , 1988, Neuroendocrinology.

[30]  I. Gozes,et al.  Developmental expression of the VIP-gene in brain and intestine. , 1987, Brain research.

[31]  L. Eiden,et al.  Vasoactive intestinal peptide and electrical activity influence neuronal survival. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Siegel,et al.  Neurotrophic action of VIP on spinal cord cultures , 1985, Peptides.

[33]  W. Rostène,et al.  Behavioural actions of vasoactive intestinal peptide (VIP) , 1984, Neuropeptides.

[34]  R. Magnus.  BEHAVIOURAL ACTIONS OF VASOACTIVE INTESTINAL PEPTIDE (VIP) , 1984 .

[35]  V. Mutt,et al.  Polypeptide with Broad Biological Activity: Isolation from Small Intestine , 1970, Science.